Ohr Pharmaceutical (NASDAQ: OHRP) 65.4% LOWER; announced the topline results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). In the intent-to-treat (ITT-LOCF) population with classic containing choroidal neovascularization (CNV) (OHR-102 n=38, Lucentis® monotherapy n=32), 42% of the patients receiving OHR-102 achieved a 3 line gain at nine months, as compared
previous post